Regeneron up on Ophthotech's stumble; shares ahead 3% premarket

|About: Regeneron Pharmaceutic... (REGN)|By:, SA News Editor

Regeneron Pharmaceuticals (NASDAQ:REGN) perks up 3% premarket on light volume in response to Ophthotech's Fovista flop. Investors apparently like the improved the outlook for EYLEA (aflibercept) due to the elimination of a potential competitor in the wet AMD space.

Subscribe for full text news in your inbox